Activation of the Tumor Suppressor PP2A Emerges as a Potential Therapeutic Strategy for Treating Prostate Cancer

摘要: Protein phosphatase 2A (PP2A) is a tumor suppressor complex that has recently been reported as novel and highly relevant molecular target in prostate cancer (PCa). However, its potential therapeutic value remains to be fully clarified. We treated PC-3 LNCaP cell lines with the PP2A activators forskolin FTY720 alone or combined inhibitor okadaic acid. examined activity, growth, prostasphere formation, levels of phosphorylation, CIP2A SET expression, AKT ERK activation. Interestingly, both dephosphorylated activated PP2A, impairing proliferation formation inducing changes phosphorylation. Moreover, led reduced levels. Treatment acid impaired activation thus demonstrating antitumoral PP2A-dependent mechanism action FTY720. Levels phosphorylation together protein expression were studied 24 PCa patients associated high Gleason scores presence metastatic disease. Altogether, our results suggest inhibition could involved progression, use PP2A-activating drugs might represent alternative strategy for treating patients.